Tirzepatide During ECT: One Case

A 2026 case report describes one patient with refractory major depressive disorder who was taking tirzepatide and completed 17 electroconvulsive therapy treatments without complications under a locally developed fasting approach^[1]. This is a case report, not a clinical trial. It shows that one planned course was completed, but it cannot estimate aspiration risk, compare fasting strategies or prove that the protocol would work for another patient. The accessible abstract does not provide the protocol details, so this article does not reproduce them or turn them into instructions.

Why repeated ECT changes the question

Electroconvulsive therapy is usually delivered under general anesthesia, often without a secured airway. Retained stomach contents therefore matter because material entering the airway can cause aspiration. The case authors describe the practical conflict clearly: a 24-hour clear-liquid diet before frequent sessions can burden the patient, while repeated rapid-sequence intubation may lengthen treatment and recovery^[1]. Those concerns sit outside the usual one-off procedure model. A person receiving ECT several times in a short period may face the same fasting decision again and again while continuity of psychiatric treatment also matters.

The drug side of that conflict is plausible but not simple. GLP-1 receptor agonists can slow gastric emptying, and reviews have found retained gastric contents more often in users than in non-users. Yet aspiration remains uncommon, and observational results do not consistently show that GLP-1 therapy raises the event rate^[2]. The tirzepatide safety overview explains the broader adverse-event evidence, while the tirzepatide research summary separates controlled outcomes from individual reports.

What the report actually supports

The report supports a narrow observation. The patient was taking tirzepatide, local ECT and anesthesia leaders created a pre-ECT fasting protocol, and 17 treatments were completed without reported complications^[1]. It does not establish which element prevented a complication. It also does not provide a comparison with medication withholding, another fasting schedule, gastric ultrasound or airway protection. A complication-free course in one person cannot show that the underlying risk was absent.

The abstract also frames treatment consistency as part of the clinical problem. That does not mean tirzepatide should always be continued through ECT, or that interruption is harmless. It means the decision has competing consequences that need individual review. Current perioperative consensus work addresses both medication management and fasting times, but recommendations differ across professional statements because the evidence base is limited^[4]. The case should therefore be read as a description of multidisciplinary planning, not a universal schedule.

How this fits the wider evidence

A 2024 scoping review found 24 eligible reports and studies. Seven of eight comparative studies reported more residual gastric contents among GLP-1 users, with ranges of 19% to 56% in users and 5% to 20% in non-users. The same review found no significant difference in aspiration events in the three retrospective comparisons that evaluated them, while noting major confounding and wide variation across designs^[2]. This combination matters: more retained contents is a meaningful anesthesia concern, but it is not the same as a measured increase in aspiration incidence.

A separate clinical review reached a similarly cautious position. It reported that retained gastric contents occur more often with GLP-1 receptor agonists, while pulmonary aspiration is rare and estimates conflict. The authors wrote that prolonged solid-food fasting and point-of-care gastric ultrasound may help, but they also described these approaches as areas needing further study^[3]. Readers comparing class evidence can use the semaglutide overview and its research section, but data from one molecule or setting should not be treated as a direct answer for every ECT patient.

Earlier literature also included an ECT case involving semaglutide. The scoping review summarizes that patient as having one uneventful treatment after a risk-benefit discussion, followed by nine uneventful treatments with semaglutide held for one week before sessions^[2]. That is another single-person course with a different drug and management pattern. It cannot validate the 2026 protocol or show that one approach is better. The semaglutide safety section provides context beyond this small ECT literature.

What clinicians and patients should ask

Coordinated assessment is the practical task. ECT teams need an accurate medication history, including the exact product and timing, while anesthesia staff need to consider gastrointestinal symptoms and other factors that can delay emptying. Prescribing clinicians may need to weigh what a change means for diabetes or weight-management care. These are clinician decisions, not steps a patient should improvise from a case report. Product status and prescribing context also vary by country, as summarized on the tirzepatide regulation pages.

The absence of symptoms cannot by itself prove an empty stomach, and a delayed procedure has consequences of its own. A shared plan should be documented before the treatment day and revisited when the medication, symptoms or ECT schedule changes. General information about semaglutide regulation should not be substituted for the clinical plan for tirzepatide, even though both involve GLP-1 receptor activity.

What we do not yet know

The published abstract does not disclose the new protocol's exact fasting windows, whether tirzepatide was continued unchanged, whether gastric ultrasound was used or how aspiration risk was assessed before each session. It gives no comparator and no estimate of treatment effect. It also cannot tell us whether the same result would occur during dose escalation, in a patient with active gastrointestinal symptoms, or with other conditions that affect gastric emptying. Larger prospective evidence is needed to compare strategies and record both aspiration-related outcomes and interruptions to ECT. The tirzepatide research record will need evidence beyond individual cases before this question can be answered. Until then, the 17-session course is useful as a clinical example, not as proof of safety.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.